CytomX Therapeutics, Inc.
(NASDAQ : CTMX)

( )
CTMX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.53%87.991.3%$894.47m
AMGNAmgen Inc.
0.04%191.311.2%$560.48m
ONCESpark Therapeutics, Inc.
0.33%113.9611.2%$458.43m
GILDGilead Sciences, Inc.
-0.93%65.020.9%$450.52m
BIIBBiogen Inc.
-1.28%325.651.3%$354.96m
BPTHBio-Path Holdings, Inc.
-5.48%27.79190.1%$296.94m
REGNRegeneron Pharmaceuticals, Inc.
-1.66%407.602.6%$280.72m
ILMNIllumina, Inc.
-1.31%305.783.5%$269.47m
VRTXVertex Pharmaceuticals Incorporated
-0.32%187.481.9%$245.27m
SRPTSarepta Therapeutics, Inc.
-1.20%126.8215.4%$210.77m
EXASExact Sciences Corporation
-3.44%91.9325.3%$194.56m
ALXNAlexion Pharmaceuticals, Inc.
-1.90%133.512.0%$181.24m
AAgilent Technologies, Inc.
-0.16%80.971.6%$153.74m
IONSIonis Pharmaceuticals, Inc.
1.25%79.528.3%$101.55m
BMRNBioMarin Pharmaceutical Inc.
-1.24%93.364.3%$97.41m

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.